FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3162193517> ?p ?o ?g. }

• W3162193517 abstract "Purpose of reviewThis review presents a comprehensive analysis of the current high-efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis (MS). We discuss the existing approved and emerging therapeutics in patients with relapsing and progressive forms of MS using data from clinical trials and observational studies. Treatment considerations in pediatric and pregnant populations are also reviewed. Finally, we discuss the treatment paradigms of the escalation and early aggressive approaches to treatment of MS, with review of ongoing clinical trials to compare these approaches.Recent findingsNatalizumab has shown promising data on efficacy in not only randomized trials but also observational studies when compared with placebo, the injectable DMTs, and fingolimod. The anti-CD20 B cell depleting therapies (rituximab, ocrelizumab, and ofatumumab) have also demonstrated superiority in randomized clinical trials compared to their comparator group (placebo, interferon, and teriflunomide, respectively) and rituximab has shown in observational studies to be more effective than older injectable therapies and some of the oral therapies. Alemtuzumab has shown good efficacy in randomized controlled trials and observational studies yet has several potentially severe side effects limiting its use. Mitoxantrone has similarly demonstrated significant reduction in new disease activity compared to placebo but is rarely used due to its severe side effects. Cladribine is an oral DMT often grouped in discussion with other higher efficacy DMTs but may be slightly less effective than the other therapies described in this review. Many emerging targets for therapeutic intervention are currently under investigation that may prove to be beneficial in early aggressive MS, including autologous hematopoietic stem cell transplantation.SummaryTraditionally, MS has been treated with an escalation approach, starting patients on a modestly effective DMT and subsequently escalating to a higher efficacy DMT when there is evidence of clinical and/or radiologic breakthrough activity. With the development of higher efficacy therapies and emerging data showing the potential positive long-term impact of these therapies when started earlier in the disease course, many clinicians have shifted to an early aggressive treatment approach in which patients are initially started on a higher efficacy DMT. Two clinical trials, the TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial and the Determining the Effectiveness of earLy Intensive Versus Escalation approaches for the treatment of Relapsing-remitting MS (DELIVER-MS) trial, aim to directly compare these treatment strategies and their impact on clinical and radiologic outcomes." @default.
• W3162193517 created "2021-05-24" @default.
• W3162193517 creator A5010022210 @default.
• W3162193517 creator A5016709769 @default.
• W3162193517 creator A5080257392 @default.
• W3162193517 date "2021-05-15" @default.
• W3162193517 modified "2023-10-10" @default.
• W3162193517 title "Early Aggressive Treatment Approaches for Multiple Sclerosis" @default.
• W3162193517 cites W1744068626 @default.
• W3162193517 cites W1803778850 @default.
• W3162193517 cites W1910618472 @default.
• W3162193517 cites W1966515383 @default.
• W3162193517 cites W1993815385 @default.
• W3162193517 cites W1998275001 @default.
• W3162193517 cites W1999175233 @default.
• W3162193517 cites W2014602172 @default.
• W3162193517 cites W2020134202 @default.
• W3162193517 cites W2025697993 @default.
• W3162193517 cites W2027894320 @default.
• W3162193517 cites W2036863084 @default.
• W3162193517 cites W2042983418 @default.
• W3162193517 cites W2054962526 @default.
• W3162193517 cites W2058583207 @default.
• W3162193517 cites W2059889458 @default.
• W3162193517 cites W2063591769 @default.
• W3162193517 cites W2077200500 @default.
• W3162193517 cites W2103758700 @default.
• W3162193517 cites W2107008240 @default.
• W3162193517 cites W2111940537 @default.
• W3162193517 cites W2114360739 @default.
• W3162193517 cites W2119172537 @default.
• W3162193517 cites W2139204856 @default.
• W3162193517 cites W2141111992 @default.
• W3162193517 cites W2142237698 @default.
• W3162193517 cites W2142577589 @default.
• W3162193517 cites W2143953700 @default.
• W3162193517 cites W2146853951 @default.
• W3162193517 cites W2148766438 @default.
• W3162193517 cites W2158202057 @default.
• W3162193517 cites W2282058593 @default.
• W3162193517 cites W2302597872 @default.
• W3162193517 cites W2313484897 @default.
• W3162193517 cites W2345469235 @default.
• W3162193517 cites W2463810424 @default.
• W3162193517 cites W2469906895 @default.
• W3162193517 cites W2527555398 @default.
• W3162193517 cites W2549031268 @default.
• W3162193517 cites W2555183069 @default.
• W3162193517 cites W2555704012 @default.
• W3162193517 cites W2558170458 @default.
• W3162193517 cites W2561881161 @default.
• W3162193517 cites W2565433170 @default.
• W3162193517 cites W2586480138 @default.
• W3162193517 cites W2593002358 @default.
• W3162193517 cites W2601204837 @default.
• W3162193517 cites W2734442974 @default.
• W3162193517 cites W2784268727 @default.
• W3162193517 cites W2801562584 @default.
• W3162193517 cites W2808883656 @default.
• W3162193517 cites W2890515892 @default.
• W3162193517 cites W2896092607 @default.
• W3162193517 cites W2910867209 @default.
• W3162193517 cites W2912026765 @default.
• W3162193517 cites W2913689423 @default.
• W3162193517 cites W2915372679 @default.
• W3162193517 cites W2916309316 @default.
• W3162193517 cites W2916478209 @default.
• W3162193517 cites W2917118951 @default.
• W3162193517 cites W2918535958 @default.
• W3162193517 cites W2944582362 @default.
• W3162193517 cites W2950659494 @default.
• W3162193517 cites W2973164339 @default.
• W3162193517 cites W2977883158 @default.
• W3162193517 cites W2988019951 @default.
• W3162193517 cites W2994302013 @default.
• W3162193517 cites W3002893796 @default.
• W3162193517 cites W3012517977 @default.
• W3162193517 cites W3014545366 @default.
• W3162193517 cites W3014628141 @default.
• W3162193517 cites W3015607380 @default.
• W3162193517 cites W3017914220 @default.
• W3162193517 cites W3022375169 @default.
• W3162193517 cites W3022913130 @default.
• W3162193517 cites W3047302551 @default.
• W3162193517 cites W3049317655 @default.
• W3162193517 cites W3093926168 @default.
• W3162193517 cites W4243002068 @default.
• W3162193517 doi "https://doi.org/10.1007/s11940-021-00677-1" @default.
• W3162193517 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8121641" @default.
• W3162193517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34025110" @default.
• W3162193517 hasPublicationYear "2021" @default.
• W3162193517 type Work @default.
• W3162193517 sameAs 3162193517 @default.
• W3162193517 citedByCount "40" @default.
• W3162193517 countsByYear W31621935172021 @default.
• W3162193517 countsByYear W31621935172022 @default.
• W3162193517 countsByYear W31621935172023 @default.
• W3162193517 crossrefType "journal-article" @default.
• W3162193517 hasAuthorship W3162193517A5010022210 @default.
• W3162193517 hasAuthorship W3162193517A5016709769 @default.

• next